BVS RSI Chart
Last 7 days
-0.2%
Last 30 days
20.1%
Last 90 days
4.0%
Trailing 12 Months
236.4%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 513.9M | 510.6M | 502.8M | 512.3M |
2022 | 466.4M | 496.9M | 516.7M | 512.1M |
2021 | 324.3M | 376.1M | 399.1M | 430.9M |
2020 | 335.4M | 330.7M | 325.9M | 321.2M |
2019 | 0 | 0 | 0 | 340.1M |
2018 | 0 | 0 | 0 | 319.2M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Mar 22, 2024 | singleton mark leonard | sold | -29,852 | 5.3876 | -5,541 | svp & cfo |
Mar 21, 2024 | singleton mark leonard | acquired | - | - | 18,625 | svp & cfo |
Mar 15, 2024 | church katrina j | sold | -6,644 | 5.46 | -1,217 | svp & chief compliance officer |
Mar 15, 2024 | d'adamio anthony | sold | -17,062 | 5.46 | -3,125 | svp & general counsel |
Mar 14, 2024 | church katrina j | acquired | - | - | 3,456 | svp & chief compliance officer |
Mar 14, 2024 | d'adamio anthony | acquired | - | - | 8,886 | svp & general counsel |
Aug 18, 2023 | bihl anthony p iii | bought | 110,071 | 4.1388 | 26,595 | interim ceo |
Aug 18, 2023 | bihl anthony p iii | bought | 55,004 | 4.1388 | 13,290 | interim ceo |
Aug 16, 2023 | nohra guy p | acquired | - | - | 41,369 | - |
Aug 16, 2023 | nohra guy p | sold | - | - | -2,604,260 | - |
Which funds bought or sold BVS recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Mar 11, 2024 | VANGUARD GROUP INC | added | 1.45 | 2,457,930 | 6,421,500 | -% |
Mar 01, 2024 | GOLDMAN SACHS GROUP INC | new | - | 362,428 | 362,428 | -% |
Feb 26, 2024 | Virtu Financial LLC | sold off | -100 | -66,000 | - | -% |
Feb 16, 2024 | PRICE T ROWE ASSOCIATES INC /MD/ | sold off | -100 | -207,000 | - | -% |
Feb 16, 2024 | PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO | sold off | -100 | -4,000 | - | -% |
Feb 15, 2024 | BARCLAYS PLC | added | 65.21 | 195,000 | 314,000 | -% |
Feb 15, 2024 | State of Wyoming | reduced | -43.21 | -6,240 | 60,842 | 0.01% |
Feb 15, 2024 | JANE STREET GROUP, LLC | added | 398 | 717,154 | 820,276 | -% |
Feb 15, 2024 | Nantahala Capital Management, LLC | added | 98.64 | 43,141,400 | 63,002,500 | 1.88% |
Feb 14, 2024 | ExodusPoint Capital Management, LP | new | - | 184,000 | 184,000 | -% |
Unveiling Bioventus Inc.'s Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Bioventus Inc.)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
ABT | 196.9B | 40.1B | 34.4 | 4.91 | ||||
BDX | 71.2B | 19.5B | 56.69 | 3.65 | ||||
ALGN | 24.6B | 3.9B | 55.33 | 6.38 | ||||
BAX | 21.7B | 14.8B | 8.16 | 1.46 | ||||
MID-CAP | ||||||||
BIO | 10.2B | 2.7B | -16.04 | 3.83 | ||||
HSIC | 9.7B | 12.3B | 23.21 | 0.78 | ||||
ATR | 9.5B | 3.5B | 33.57 | 2.74 | ||||
XRAY | 6.9B | 4.0B | -51.36 | 1.74 | ||||
AXNX | 3.5B | 366.4M | -577.22 | 9.59 | ||||
PDCO | 2.5B | 6.6B | 12.86 | 0.38 | ||||
SMALL-CAP | ||||||||
AHCO | 1.5B | 3.2B | -2.23 | 0.47 | ||||
ANIK | 379.3M | 166.7M | -4.59 | 2.28 | ||||
ANGO | 227.2M | 329.5M | -16.09 | 0.69 | ||||
APYX | 43.3M | 52.3M | -2.31 | 0.83 | ||||
AEMD | 4.5M | 3.7M | -0.37 | 1.19 |
Bioventus Inc. News
Income Statement (Quarterly) | |||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2018Q4 |
Revenue | 12.1% | 135 | 121 | 137 | 119 | 126 | 129 | 140 | 117 | 130 | 109 | 110 | 82.00 | 99.00 | 86.00 | 58.00 | 79.00 | - | - |
Gross Profit | 9.4% | 86.00 | 79.00 | 89.00 | 74.00 | 74.00 | 85.00 | 97.00 | 76.00 | 88.00 | 79.00 | 76.00 | 60.00 | 73.00 | 62.00 | 40.00 | 57.00 | - | - |
S&GA Expenses | 12.2% | 78.00 | 70.00 | 75.00 | 81.00 | 78.00 | 79.00 | 90.00 | 86.00 | 81.00 | 70.00 | 69.00 | 35.00 | 62.00 | 50.00 | 41.00 | 40.00 | - | - |
R&D Expenses | 8.2% | 3.00 | 3.00 | 3.00 | 4.00 | 8.00 | 5.00 | 6.00 | 7.00 | 7.00 | 6.00 | 5.00 | 1.00 | 3.00 | 4.00 | 3.00 | 2.00 | - | - |
EBITDA Margin | 45.0% | -0.22* | -0.40* | -0.63* | -0.63* | -0.47* | -0.29* | -0.05* | -0.06* | 0.04* | 0.06* | 0.09* | 0.12* | 0.07* | 0.05* | 0.05* | 0.05* | 0.05* | 0.05* |
Income Taxes | -225.0% | -0.75 | 1.00 | 0.00 | -0.15 | -17.10 | -29.52 | 1.00 | -5.13 | -2.72 | -0.88 | 2.00 | -0.07 | 1.00 | 0.00 | -0.11 | 0.00 | - | - |
Earnings Before Taxes | -2.6% | -8.41 | -8.19 | -4.35 | -100 | -107 | -130 | -6.49 | -19.54 | -4.62 | -3.15 | -9.07 | 24.00 | 3.00 | 8.00 | -6.09 | 11.00 | - | - |
EBT Margin | 46.0% | -0.24* | -0.44* | -0.67* | -0.67* | -0.52* | -0.31* | -0.07* | -0.08* | 0.02* | 0.04* | 0.07* | 0.09* | 0.05* | 0.03* | 0.03* | 0.03* | 0.03* | 0.02* |
Net Income | 16.5% | -6.10 | -7.30 | -3.68 | -139 | -31.93 | -108 | -7.25 | -11.28 | -0.36 | -1.07 | -4.13 | -1.04 | 3.00 | 8.00 | -5.77 | 11.00 | - | - |
Net Income Margin | 15.8% | -0.30* | -0.36* | -0.55* | -0.56* | -0.31* | -0.25* | -0.04* | -0.04* | -0.02* | 0.04* | 0.04* | 0.05* | 0.05* | 0.02* | 0.02* | 0.02* | 0.02* | -0.04* |
Free Cashflow | 196.7% | 10.00 | -10.35 | 9.00 | -1.07 | 2.00 | -2.35 | 1.00 | -23.98 | 10.00 | 9.00 | 16.00 | -19.41 | 11.00 | 20.00 | 7.00 | 17.00 | - | - |
Balance Sheet | |||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2019Q4 |
Assets | 0.0% | 811 | 811 | 837 | 887 | 1,373 | 1,398 | 1,209 | 1,197 | 1,226 | 655 | 647 | 643 | 494 | 472 |
Current Assets | 7.4% | 268 | 249 | 261 | 309 | 273 | 271 | 277 | 245 | 263 | 246 | 290 | 271 | 212 | 183 |
Cash Equivalents | 37.8% | 37.00 | 27.00 | 29.00 | 47.00 | 30.00 | 34.00 | 41.00 | 83.00 | 99.00 | 131 | 138 | 129 | 87.00 | 65.00 |
Inventory | -6.4% | 91.00 | 98.00 | 96.00 | 88.00 | 85.00 | 77.00 | 69.00 | 65.00 | 62.00 | 37.00 | 34.00 | 40.00 | 29.00 | 27.00 |
Net PPE | - | - | - | - | - | - | - | - | 25.00 | 23.00 | 10.00 | 9.00 | 8.00 | 7.00 | 4.00 |
Goodwill | 0% | 7.00 | 7.00 | 7.00 | 7.00 | 7.00 | 15.00 | 60.00 | 148 | 148 | 53.00 | 52.00 | 3.00 | 50.00 | 50.00 |
Liabilities | 0.9% | 590 | 585 | 604 | 647 | 960 | 1,019 | 689 | 675 | 618 | 424 | 427 | 423 | 350 | 327 |
Current Liabilities | 9.1% | 175 | 161 | 179 | 196 | 304 | 288 | 199 | 172 | 181 | 161 | 158 | 149 | 123 | 89.00 |
Long Term Debt | -100.0% | - | 375 | 375 | 404 | 385 | 393 | 351 | 348 | 340 | 162 | 166 | 170 | 173 | 188 |
LT Debt, Current | 42.2% | 28.00 | 20.00 | 11.00 | 41.00 | 33.00 | 31.00 | 23.00 | 20.00 | 18.00 | 15.00 | 15.00 | 15.00 | 15.00 | 10.00 |
LT Debt, Non Current | -2.1% | 367 | 375 | 375 | 404 | 385 | 393 | 351 | 348 | 340 | 162 | 166 | 170 | 173 | 188 |
Shareholder's Equity | 24.6% | 221 | 178 | 233 | 240 | 325 | 451 | 592 | 594 | 608 | 230 | 219 | 220 | 144 | 143 |
Retained Earnings | -1.9% | -321 | -315 | -308 | -304 | -165 | -133 | -25.13 | -17.88 | -6.60 | -6.24 | -5.17 | -1.04 | -144 | -141 |
Additional Paid-In Capital | 0.4% | 494 | 492 | 491 | 492 | 491 | 478 | 474 | 468 | 473 | 158 | 146 | 143 | - | - |
Shares Outstanding | -100.0% | - | 62.00 | 62.00 | 62.00 | 61.00 | 62.00 | 61.00 | 60.00 | 45.00 | 42.00 | 42.00 | 42.00 | - | - |
Minority Interest | -2.9% | 48.00 | 49.00 | 50.00 | 52.00 | 87.00 | 36.00 | 72.00 | 72.00 | 141 | 78.00 | 78.00 | 78.00 | 2.00 | 3.00 |
Cashflow (Quarterly) | |||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2018Q4 |
Cashflow From Operations | 224.8% | 10,374 | -8,315 | 10,795 | 2,490 | 5,244 | -701 | 2,939 | -21,019 | 13,117 | 10,587 | 17,329 | -18,042 | 25,447 | 20,841 | 7,820 | 17,691 | - | - |
Share Based Compensation | -3.2% | 1,775 | 1,833 | -2,732 | 1,846 | 3,432 | 4,648 | 4,616 | 4,889 | 6,109 | 5,938 | 5,853 | 1,944 | - | - | - | - | - | - |
Cashflow From Investing | 71.0% | -591 | -2,036 | 33,500 | -15,066 | -3,403 | -56,334 | -52,025 | -4,674 | -221,278 | -13,186 | -2,648 | -46,648 | -1,711 | -17,759 | -579 | -451 | - | - |
Cashflow From Financing | -100.2% | -14.00 | 8,229 | -62,248 | 27,380 | -5,438 | 50,654 | 7,655 | 9,205 | 176,308 | -4,346 | -6,117 | 107,526 | -9,878 | -57,116 | -11,357 | 48,782 | - | - |
Consolidated Statements of Operations and Comprehensive (Loss) Income - USD ($) $ in Thousands | 12 Months Ended | ||||
---|---|---|---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |||
Income Statement [Abstract] | |||||
Net sales | $ 512,345 | $ 512,117 | $ 430,898 | ||
Cost of sales (including depreciation and amortization of $48,503, $45,622 and $26,471 respectively) | 184,152 | 181,037 | 128,192 | ||
Gross profit | 328,193 | 331,080 | 302,706 | ||
Selling, general and administrative expense | 303,879 | 332,134 | 254,253 | ||
Research and development expense | 13,446 | 23,854 | 19,039 | ||
Restructuring costs | 840 | 6,779 | 2,487 | ||
Change in fair value of contingent consideration | 719 | 1,102 | 829 | ||
Depreciation and amortization | 8,842 | 9,748 | 8,363 | ||
Impairment of assets | 78,615 | 0 | 0 | ||
Impairment of goodwill | 0 | 124,697 | 0 | ||
Loss on disposals | 3,577 | 0 | 0 | ||
Impairment of variable interest entity assets | 0 | 0 | 5,674 | ||
Operating (loss) income | (81,725) | (167,234) | 12,061 | ||
Interest expense, net | 40,676 | 12,021 | 1,112 | ||
Other (income) expense | (1,290) | 9,770 | 1,461 | ||
Other expense | 39,386 | 21,791 | 2,573 | ||
(Loss) income before income taxes | (121,111) | (189,025) | 9,488 | ||
Income tax expense (benefit), net | 85 | (44,374) | (1,966) | ||
Net (loss) income from continuing operations | (121,196) | (144,651) | 11,454 | ||
Loss from discontinued operations, net of tax | (74,429) | (68,740) | (1,868) | ||
Net (loss) income | (195,625) | (213,391) | 9,586 | ||
Loss attributable to noncontrolling interest - continuing operations | 24,458 | 40,732 | 9,789 | ||
Loss attributable to noncontrolling interest - discontinued operations | 14,937 | 13,955 | 0 | ||
Net (loss) income attributable to Bioventus Inc. | (156,230) | (158,704) | 19,375 | ||
Change in prior service cost and unrecognized (loss) gain for defined benefit plan adjustment | (8) | 133 | 60 | ||
Change in foreign currency translation adjustments | 1,140 | (501) | (1,318) | ||
Comprehensive (loss) income | (194,493) | (213,759) | 8,328 | ||
Comprehensive loss attributable to noncontrolling interest - continuing operations | 24,230 | 40,811 | 9,789 | ||
Comprehensive loss attributable to noncontrolling interest - discontinued operations | 14,937 | 13,955 | 0 | ||
Comprehensive (loss) income attributable to Bioventus Inc. | $ (155,326) | $ (158,993) | $ 18,117 | ||
Loss per share of Class A common stock | |||||
Continuing operations, basic (in dollars per share) | [1] | $ (1.54) | $ (1.70) | $ (0.11) | |
Continuing operations, diluted (in dollars per share) | [1] | (1.54) | (1.70) | (0.11) | |
Discontinued operations, basic (in dollars per share) | [1] | (0.95) | (0.89) | (0.04) | |
Discontinued operations, diluted (in dollars per share) | [1] | (0.95) | (0.89) | (0.04) | |
Basic (in dollars per share) | [1] | (2.49) | (2.59) | (0.15) | |
Diluted (in dollars per share) | [1] | $ (2.49) | $ (2.59) | $ (0.15) | |
Weighted-average shares of Class A common stock outstanding | |||||
Basic (in shares) | [1] | 62,647,554 | 61,389,107 | 45,472,483 | |
Diluted (in shares) | [1] | 62,647,554 | 61,389,107 | 45,472,483 | |
|
Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 36,964 | $ 30,186 |
Accounts receivable, net | 122,789 | 136,295 |
Inventory | 91,333 | 84,766 |
Prepaid and other current assets | 16,913 | 18,551 |
Current assets attributable to discontinued operations | 0 | 2,777 |
Total current assets | 267,999 | 272,575 |
Property and equipment, net | 36,605 | 27,456 |
Goodwill | 7,462 | 7,462 |
Intangible assets, net | 482,350 | 639,851 |
Operating lease assets | 13,353 | 16,690 |
Investment and other assets | 3,141 | 2,621 |
Long-term assets attributable to discontinued operations | 0 | 405,994 |
Total assets | 810,910 | 1,372,649 |
Current liabilities: | ||
Accounts payable | 23,038 | 36,697 |
Accrued liabilities | 119,795 | 111,570 |
Current portion of long-term debt | 27,848 | 33,056 |
Other current liabilities | 4,816 | 3,607 |
Current liabilities attributable to discontinued operations | 0 | 119,087 |
Total current liabilities | 175,497 | 304,017 |
Long-term debt, less current portion | 366,998 | 385,010 |
Deferred income taxes | 1,213 | 2,248 |
Contingent consideration | 18,150 | 17,431 |
Other long-term liabilities | 27,934 | 22,810 |
Long-term liabilities attributable to discontinued operations | 0 | 228,911 |
Total liabilities | 589,792 | 960,427 |
Commitments and contingencies (Note 12) | ||
Stockholders’ Equity: | ||
Additional paid-in capital | 494,254 | 490,576 |
Accumulated deficit | (321,536) | (165,306) |
Accumulated other comprehensive income (loss) | 794 | (110) |
Total stockholders’ equity attributable to Bioventus Inc. | 173,591 | 325,238 |
Noncontrolling interest | 47,527 | 86,984 |
Total stockholders’ equity | 221,118 | 412,222 |
Total liabilities and stockholders’ equity | 810,910 | 1,372,649 |
Common Class A | ||
Stockholders’ Equity: | ||
Common stock, value | 63 | 62 |
Common Class B | ||
Stockholders’ Equity: | ||
Common stock, value | $ 16 | $ 16 |